Tyrosine kinase inhibitors for chronic myeloid leukemia: a landscape analysis of global clinical trials based on public registries.

What was studied

This study mapped clinical trials of tyrosine kinase inhibitor drugs in chronic myeloid leukemia. It searched public trial registries up to March 2026. It also checked if trial results were public. It looked at finished trials that had ended at least 2 years earlier. Reviewers screened the trials and pulled out data on their own.

What they found

125 trials were included. 96 were interventional and 23 were randomised. Most aimed at BCR-ABL1. Trial sites were mostly the United States, Europe, China and Australia. Mid-stage studies were the most common. Among 52 finished drug trials, results were public for 25. 7 of 9 late-stage trials had results. 0 of 4 earliest-stage trials had results. Results varied by drug group. No drug comparison held up after adjusting for many tests.

What it means for patients

The authors say trials are unevenly spread across places and phases. They say results are often not made public. They say future work should boost teamwork and balance trial phases. They also call for support of new drugs and timely sharing of results.

Why it is not certain yet

This study counts trials, not patient outcomes. It does not show how well any drug works. Results were sought in registries and a bibliographic search. The authors call the drug group differences descriptive.

Source

Tyrosine kinase inhibitors for chronic myeloid leukemia: a landscape analysis of global clinical trials based on public registries.

We restate facts from the source record in our own words. The original wording belongs to its publisher.